Rubicon Research Limited announced several key decisions made during its Board of Directors meeting held on February 3, 2026. Dr. Pradnya Saravade has been appointed as an Additional Independent Woman Director for a period of three years, effective from February 3, 2026, to February 2, 2029. This appointment is subject to shareholder approval. Dr. Saravade brings a wealth of experience from her career in the Indian Police Service, including roles in governance, administration, and investigations. The board also noted the resignation of Mr. Anand Agarwal as a Non-Executive Director, effective from the close of business on February 3, 2026. Mr. Agarwal cited other pressing commitments for his decision. Furthermore, M/s. BNP & Associates, a firm of Practicing Company Secretaries, has been approved as the Secretarial Auditor for FY 2025-26 and the subsequent four years until FY 2029-30, also pending member approval. In a significant strategic move, the board granted in-principle approval for the merger of KIA Health Tech Private Limited, a wholly-owned subsidiary, with Rubicon Research Limited. This merger is subject to board approval of the scheme of arrangement, regulatory approvals, and other administrative formalities. The rationale for the merger is to achieve operational synergies. As of March 31, 2025, KIA Health Tech had a net-worth of ₹815.80 Lakhs and nil revenue, while Rubicon Research had a net-worth of ₹66,778.57 Lakhs and total revenue of ₹1,09,352.40 Lakhs. The merger will not involve cash consideration or change the shareholding pattern of Rubicon Research Limited.
